Table 3.
Variables | Rapid GFR decline (>3 mL/min/1.73 m2/year) |
p-values | |
---|---|---|---|
No (n = 375) |
Yes (n = 144) |
||
Age (years) | 37 ± 9 | 34 ± 9 | <0.0001 |
Duration (years) | 24 ± 9 | 21 ± 8 | 0.003 |
HbA1c (%) | 7.9 ± 1.1 | 8.0 ± 1.5 | 0.58 |
HbA1c (mmol/mol) | 63 ± 12 | 64 ± 16 | 0.58 |
BMI (kg/m2) | 26 ± 4 | 26 ± 5 | 0.69 |
ACEi/ARB (yes, %) | 35 (133) | 22 (32) | 0.004 |
Adiponectin at baseline (μg/ml) | 14.7 ± 7.9 | 17.0 ± 10.3 | 0.02 |
Adiponectin at 6-year follow-up (μg/ml) | 14.9 ± 8.9 | 16.2 ± 10.8 | 0.15 |
CRP* at baseline (mg/l) | 2.5 (2.4–2.6) | 2.7 (2.5–3.0) | 0.10 |
AER* at baseline (μg/min) | 9 (8–11) | 10 (8–13) | 0.44 |
AER* at 6-year follow-up (μg/min) | 8 (7–9) | 10 (7–13) | 0.24 |
ACR* at baseline (mg/g) | 9 (8–10) | 11 (9–15) | 0.08 |
ACR* at 6-year follow-up (mg/g) | 8 (7–9) | 10 (8–13) | 0.07 |
eGFR by CKD-EPI creatinine (mL/min/1.73 m2) | 98 ± 25 | 121 ± 20 | <0.0001 |
eGFR by CKD-EPI creatinine at 6-year follow-up (mL/min/1.73 m2) | 101 ± 21 | 91 ± 22 | <0.0001 |
Includes only participants with complete eGFR at baseline and follow-up.
Geometric means ± 95% confidence interval.